GENE has the right test at the right time. It is happening now. All women are going to be genetically tested for breast and ovarian cancer in the next few years. Sky is the limit for GENE.
It's going to be released anyday now. They are discovering that there are many more genes besides BRCA that cause breast cancer. The data from the next PR is going to show Brevagenplus is much more powerful predictor than the normal test for those that test negative for BRCA.
That's fine. When we blast past $10 again soon we will have $19 million of their money too. Is this a great country or what?
Clinical validation publication regarding their expanded SNP panel is going to be released soon!
But what do I know, I have only been in a long in this company for 5 years now.... ;)
$18 million + $24 million standby. Why are they accumulating all this cash? It's obvious they are about to buy something or someone. Or really expand BrevagenPlus very quickly. Time to go shopping!
This is the best you got? haha You have no idea what you are talking about. I am going to enjoy watching you guys squeal all the way to $50 and beyond. Are you the guy paying me 30% to borrow my shares?
subject matter eligibility exceptions to will “eviscerate patent law”? If successful, GENE will be awarded a windfall for shareholders as they are suing large pharma Bristol-Myers, Glaxo, Pfizer to name a few. Q4 2015 $$$$
6) Acquire U.S lab to gain approval for Medicare and Obamacare. Their ex-CEO told me last year that was being considered in their long term strategic plan. 2015-2016 $$$$
7) Selling or partnering up with someone on their prenatal test Rarecellect. They said in the annual meeting with shareholders that they might have a deal by end of year. Not sure how much they could get or if a partner would be profitable. But is interesting technology. 2015 $
8) Accelerated sales increase. Company is really projecting blockbuster sales starting in Q3 2015 with the new breast cancer centers they are signing. According to their presentation at the recent annual meeting, they are forecasting 16,000 tests sold next year, 25,000 in 2016, 41,000 in 2017. Cash cow in less than three years. $$$$.
I have been a (bag) holder of this stock for the past 4 years and have followed the company closely through all the crazy events that have happened. I have seen it all from their purchase of Brevagen, CEO and board resignations from the board spill by their ex-CEO and largest shareholder Mervyn Jacobson who was thrown in jail recently for manipulating the stock years ago. I have seen many new boards, CEO's and CFO's in this company over the last few years than I care to admit. I can't believe the company made it to be honest, and now I see some big catalysts over the next few years that could send the stock soaring:
1) Additional clinical validation publications of Brevagenplus expected in early to mid 2015. $$
2) Start clinical utility studies in Q3 2015 to negotiate with insurers. Q1 2016 completion. This is the most important goal for the company to achieve. A CPT code for Brevagenplus will send the stock soaring to all time highs. $$$$
3) Develop new genetic test e.g colon cancer, ovarian cancer. They have been talking about it for a while, maybe with their recent capital raise they will go shopping for one? Or partner with someone? 2015 $$$
4) Add BRCA testing to BrevagenPlus. I spoke with the ex-CEO last year and she said they were closely watching the Myriad case, which Myriad lost. About 7 years ago, Myriad gave GENE the exclusive rights to BRCA testing in Australia when GENE sued Myriad for infringing their patents. So GENE knows how to BRCA test and it makes sense to tie it into Brevagenplus. It could be announced soon, not sure what they are waiting on. 2015 $$$$
5) GENE lost a U.S District Court case last fall that invalidated it's '179 patent. Legal team is in process of filing an appeal to the Federal Circuit. Judge worries that a liberal application of the machine or transformation test would “eviscerate the holding in Mayo” but did he forget the Supreme Court’s warning in Myriad that an overly broad application of the judicially-created patent
All of this was expected. Nothing new that should cause for panic, but the algo's are doing their thing before the weekend. One thing I noticed that will easily send the stock in the $20's is this:
"Clinical utility studies have been designed and are currently proceeding through the Institutional Review Board process at a US breast cancer research institute. The data obtained from these studies will be utilized in direct contracting discussions with insurers and self-insured employer groups."
The study should be completed in the next few months. Insurers will be on board by the time sales are to pick up exponentially.
"As a consequence, we believe that Myriad will seriously consider buying either BREVAGenTM or Genetic Technologies. It is known that the two companies’ are in contact with each other, given Genetic Technologies is a licencee of some of Myriad’s patents and vice versa. While it is difficult to gauge what a deal would look like at this stage, the fact that Genetic Technologies has demonstrated commercial acceptance of BREVAGenTM, the price would likely be significant."
I still think Myriad is the one who will end up buying GENE.
FDA eases access to DNA screening for inherited diseases
Associated Press By MATTHEW PERRONE
11 hours ago
WASHINGTON (AP) — Federal health officials are easing access to DNA tests used to screen parents for devastating genetic disorders that can be passed on to their children. The surprise announcement offers a path forward for Google-backed genetic testing firm 23andMe, which previously clashed with regulators over its direct-to-consumer technology.
The Food and Drug Administration said late Thursday it will not require preliminary review before companies can sell so-called carrier screening tests to the public. The tests, currently administered by health care professionals, are used by prospective parents who are healthy but may be carriers of cystic fibrosis, Tay-Sachs and other rare familial conditions.
In the same announcement, the FDA said it cleared the first carrier screening test from 23andMe, which was forced to pull its health tests from the market in 2013 due to a lack of scientific evidence.
23andMe's test screens for the genetic mutations that cause Bloom syndrome, a rare disorder that causes short stature, increased risk of cancer and a variety of other health problems. The disorder is more common in people of central and eastern European Jewish descent, affecting about 1 in 50,000.
The positive FDA decision is a victory for Mountain View, California-based 23andMe, which had recently become something of a poster child for the culture clash between Silicon Valley and Washington.
The company's CEO Anne Wojcicki said in an interview that her company's research demonstrates that patients can understand genetic testing results.
"Our user comprehension studies have shown that people can get this information on their own without a physician and that there's potentially a real benefit to direct access," said Wojcicki.
Bloom syndrome is one of about 250 conditions and diseases that 23andMe's original DNA kit claimed to help screen for by analyzing
Look up my posts. I have been a long in this company for the past 4 years and have followed the company closely. There could be a bidding war for GENE among some major genetic players, but I believe Myriad Genetics is going to buy the company and here is why it makes perfect sense now:
1) Myriad's Supreme Court BRCA patent loss means revenue loss. Their recent earnings have disappointed from their BRCA patent loss and GENE is a perfect acquisition to make up for loss revenues. BrevagenPlus has shown market penetration, it is proven to be effective, and is starting to increase sales with more large breast centers using the test. Over the last few years as genetic sequencing has increased, so has the discovery of more gene's that could cause Breast Cancer. GENE just released BrevagenPlus which includes almost 100 new markers. All GENE would have to do is add BRCA testing and they will have the better test.
2) Myriad and GENE have made deals in the past regarding licensing BRCA testing. GENE is the sole holder of MYGN's BRCA testing license in Australia and Myriad is the licensee of GENE's non-coding patents.
3) GENE has no debt.
4) GENE and MYGN have no permanent CEO (who wants to make a deal and combine the companies?).
5) Myriad could buy GENE for tax reasons. More and more U.S Companies are buying international companies to dodge taxes.
Read this Lodge Partners analyst notes speculating on Myriad buying the company:
Myriad's valuation is close to $3 billion so it is possible. Here is how they can get there:
1) Get a CPT code for BrevagenPlus. They are having a hard time getting insurers to reimburse for the test, but if they achieve that, the stock is worth $20-30 alone on that news. They think they might be able to get it end of 2015.
2) Get Medicare to reimburse. They need a U.S Lab which they are working on. If they get Obamacare or Medicare to reimburse the sky is the limit.
3) Add BRCA testing to BrevagenPlus. Myriad's monopoly is over after the U.S Supreme Court put an end to them. This is a huge market. They already know how to BRCA test since they have owned the Australian license from Myriad for years. I spoke to the CEO last year about adding BRCA and she said they were watching the court case very closely. So IMO it is coming any day now.
4) Non-Coding Patent litigation. Nobody saw the news in the recent Quarterly, but tucked in there was they have appealed the decision to the Federal Court and some attorneys are saying they have a good chance. This could be a sleeper one day that could send the stock into orbit if the Federal Courts reverse the appeal.
5) Going global with BrevagenPlus, higher sales and adding another genetic test. We are about to see an explosion of genetic testing over the next 5-10 years.
U.S. to Develop DNA Study of One Million People
An Obama initiative seeks to channel a torrent of gene information into treatments for cancer, other diseases.
By Antonio Regalado on January 30, 2015
Medicine is being revolutionized by “population-scale” genome projects.
President Barack Obama is proposing to spend $215 million on a “precision medicine” initiative the centerpiece of which will be a national study involving the health records and DNA of one million volunteers, administration officials said yesterday.
Precision medicine refers to treatments tailored to a person’s genetic profile, an idea already transforming how doctors fight cancer and some rare diseases.
The Obama plan, including support for studies of cancer and rare disease, is part of a shift away from “one-size-fits-all” medicine, Jo Handelsman, associate director for the White House Office of Science and Technology Policy, said in a briefing yesterday. She called precision medicine “a game changer that holds the potential to revolutionize how we approach health in this country and around the world.”
The White House said the largest part of the money, $130 million, would go to the National Institutes of Health in order to create a population-scale study of how peoples’ genes, environment, and lifestyle affect their health.
According to Francis Collins, director of the National Institutes of Health, the study will recruit new volunteers as well as merging data from several large studies already under way. Details still need to be sorted out, said Collins, but the study could eventually involve completely decoding the genomes of hundreds of thousands of people.
Officials indicated that patients might have more access to data generated about them than is usually the case in research studies. That is partly because scientists will need the ability to re-contact them, should their genes prove interesting.
“We aren’t just talking about research but also about patients’ access to their own dat
Finally the market gets it. Look out Myriad. We are coming for you.